Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Personalis is a provider of genomic sequencing and analytics solutions for personalized cancer vaccines, with its latest acquisition by Tempus AI Inc implying an overall transaction value of $1.7B. With a potential for Medicare coverage and strong financials, Personalis is on track to meet its 2026 guide for $78-80M in revenue and Gross Margin of 15-20%.

Bears say

Personalis is currently facing several fundamental challenges that are likely to hinder its financial performance in the future. These challenges include a high cash burn rate, negative operating margin, and significant competition in its core markets, resulting in lower-than-expected revenues. Additionally, the company's reliance on a single segment for its revenues and a potential discount in its valuation compared to its peers contribute to our negative outlook on Personalis's stock. All of these factors combined make us believe that investing in this stock may not be a profitable venture.

Personalis Inc (PSNL) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Buy based on their latest research and market trends.

According to 6 analysts, Personalis Inc (PSNL) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.